All Blogs

Jul 24, 2026

Summary Alzheimer’s disease treatment has shifted from symptomatic management to disease modification with the emergence of anti-amyloid beta (Aβ) inhibitors that target the root cause by clearing amyloid plaques. Biogen/Eisai’s LEQEMBI and Eli Lilly’s KISUNLA are currently the only Aβ-targeting therapies to...

Jul 23, 2026

Seegene USA Received FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions On 21 July 2026, Seegene USA received U.S. FDA Emergency Use Authorization (EUA) for its Allplex™ HSV-1&2/VZV/MPXV Assay, the fir...

Jul 22, 2026

For most of modern medical history, treatment has meant managing disease, controlling symptoms, slowing progression, and buying time. Regenerative medicine flips that model on its head. Instead of managing damage, it aims to repair it: regrowing tissue, replacing diseased cells, and in some cases, reversing conditi...

Jul 21, 2026

Novartis Wins FDA Traditional Approval for Fabhalta to Treat Primary IgAN Novartis announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta (iptacopan) for slowing the progression of kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) wh...

Jul 20, 2026

Summary SARCLISA ESCENA is the first anticancer treatment approved for delivery via an on-body injector — approved in the US, EU, and UK. It's delivered via CirCLIQ, a hands-free wearable device built on Enable Injections' enFuse platform. Approval was supported by the Phase 3 IRAKLIA trial, showing effic...

Jul 16, 2026

POLYTECH Announced the Approval of an Updated Process for Microthane®  On 16 July 2026, POLYTECH Health & Aesthetics announced the approval of its updated proprietary manufacturing process for Microthane®, its polyurethane-coated breast implant technology. The company stated that the revised process was...

Jul 17, 2026

Summary H2 2026 is expected to be a highly active FDA regulatory period, with decisions spanning oncology, nephrology, infectious diseases, neurology, hematology, and rare diseases, reflecting greater therapeutic diversity beyond oncology dominance. Key innovation trends include first- and best-in-class biol...

Jul 15, 2026

For most of medical history, treating disease meant casting a wide net. Chemotherapy attacked every fast-dividing cell it could find, healthy or cancerous. Broad-spectrum drugs treated symptoms without ever asking why a particular patient's biology behaved the way it did. That era is ending. Targeted therapeutics, ...

Jul 14, 2026

Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab–Rivoceranib Combination in Advanced Liver Cancer Hengrui Pharma and Elevar Therapeutics have encountered another setback in their efforts to secure U.S. approval for the combination of camrelizumab and rivoceranib, as the FDA has issued a thir...

Jul 13, 2026

Summary ILD is a heterogeneous group of 200+ chronic lung disorders marked by inflammation and progressive scarring that cause worsening breathlessness, declining lung function, and shortened life expectancy. Monoclonal antibodies (mAbs) are reshaping ILD care by precisely targeting inflammatory and fibrotic...